Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Fig. 2

Intra-tumoral biomarkers linked to clinical outcome. a Number of patients with a BRAF (black), NRAS (orange) or BRAF/NRAS double (orange hatched) mutation in the PD and combined CBR group (CBR; CR, PR or SD ≥ 24 weeks). The frequency of BRAF and NRAS mutations in PD is significantly higher compared to CBR (Χ2 = 4.474, p = 0.03) b Graphical presentation of the baseline immune score (0: absent; 1: low; 2: moderate; 3: high peri- and intratumor CD3-+ cells) per response group (irRC criteria). Mutations type for each sample is indicated: BRAF (black), NRAS (orange) or BRAF/NRAS double (orange hatched). A significant correlation between response group and baseline immune score was observed (Pearson correlation 0.487, p = 0.01). c Baseline immune score (1: low; 2: moderate; 3: high peri- and intra-tumor CD3+ cells) and the percentage of PD-L1 expressing melanoma cells. Mutations type for each sample is indicated: BRAF (black), NRAS (orange) or BRAF/NRAS double (orange hatched). A trend towards higher PD-L1 expression with increasing baseline immune score was observed (Pearson correlation 0.386, p = 0.069). No significant difference between the percentage of PD-L1 positive melanoma cells in tumors with baseline immune score 1 and 3 (Mann Whitney U test p = 0.694)

Back to article page